Trulicity ® (dulaglutid) injektion

För fullständig produktresumé för Trulicity® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Trulicity® (dulaglutid): Varaktighet av Diabetes Mellitus

Behandling med dulaglutid resulterade i liknande minskningar av HbA1c-nivåer och FBG-koncentrationer och i allmänhet liknande förändringar i kroppsvikt oavsett varaktighet av diabetes mellitus.

Post Hoc Analysis - Duration of Diabetes Mellitus

A post hoc analysis of 7 AWARD studies, AWARD-1 to -6 and -8, assessed the efficacy and safety of once-weekly dulaglutide 1.5 mg and dulaglutide 0.75 mg in adults with T2DM when stratified into subgroups by duration of DM.1

At 6 and 12 months, all subgroups of patients treated with once-weekly dulaglutide 1.5 mg or dulaglutide 0.75 mg demonstrated a significant LSM reduction in HbA1c levels from baseline, with similar LSM reductions in HbA1c levels among duration of DM subgroups for both doses (Table 1).1

Table 1. Change in HbA1c Levels From Baseline to 6 and 12 Months With Once-Weekly Dulaglutide 1.5 mg or Dulaglutide 0.75 mg Stratified by Duration of Diabetes Mellitus - Pooled Analysis From AWARD-1 to -6 and -8 Studies1

HbA1c, %a 

Dulaglutide 1.5 mg 

Dulaglutide 1.5 mg

Dulaglutide 1.5 mg

Dulaglutide 0.75 mg 

Dulaglutide 0.75 mg

Dulaglutide 0.75 mg


<5b
(n=724)

5 to <10b
(n=601)

10b
(n=633)

<5b
(n=528)

5 to <10b
(n=370)

10b
(n=519)

Change from baseline to 6 months 

-1.32
(-1.43, -1.22)

-1.33
(-1.43, -1.22)

-1.24
(-1.35, -1.14)

-1.16
(-1.28, -1.05)

-1.12
(-1.24, -1.00)

-1.09
(-1.20, -0.98)

Change from baseline to 12 months

-1.25
(-1.37, -1.13)

-1.28
(-1.40, -1.16)

-1.21
(-1.33, -1.09)

-1.05
(-1.18, -0.92)

-0.99
(-1.13, -0.86)

-1.02
(-1.15, -0.90)

Abbreviations: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes; DM = diabetes mellitus; HbA1c = glycated hemoglobin; LSM = least squares mean.

a Data presented as LSM (95% CI). AWARD-1 to -5 studies reported data at both 6 and 12 months; AWARD-6 and -8 studies reported data at 6 months only.

b Represents duration of DM in years.

Among the duration of DM subgroups, treatment with dulaglutide 1.5 mg or dulaglutide 0.75 mg resulted in

  • similar LSM reductions in FBG concentrations at 6 and 12 months, and

  • generally similar LSM changes in body weight at 6 months.1

References

1. Gallwitz B, Dagogo-Jack S, Thieu V, et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018;20(2):409-418. http://dx.doi.org/10.1111/dom.13086

Glossary

AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes

DM = diabetes mellitus

FBG = fasting blood glucose

HbA1c = glycated hemoglobin

LSM = least squares mean

T2DM = type 2 diabetes mellitus

Datum fӧr senaste ӧversyn 2018 M10 25


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss